Verstraete M, Bleifeld W, Brower R W, Charbonnier B, Collen D, de Bono D P, Dunning A J, Lennane R J, Lubsen J, Mathey D G
Lancet. 1985 Nov 2;2(8462):965-9. doi: 10.1016/s0140-6736(85)90523-9.
In a double-blind randomised trial 129 patients with first myocardial infarction of less than 6 h duration were allocated to treatment with human recombinant tissue-type plasminogen activator (rt-PA) given intravenously over 90 min, or to placebo infusion. Coronary angiography at the end of this infusion showed that the infarct-related vessel was patent in 61% of 62 assessable coronary angiograms in the rt-PA-treated group compared with 21% in the control group. Treatment with rt-PA was not accompanied by any major complications. In the rt-PA group the circulating fibrinogen level at the end of the catheterisation was 52 +/- 29% (mean +/- SD) of the starting value.
在一项双盲随机试验中，129例首次发生心肌梗死且病程小于6小时的患者被随机分为两组，一组接受90分钟静脉滴注人重组组织型纤溶酶原激活剂（rt-PA）治疗，另一组接受安慰剂输注。输注结束时进行冠状动脉造影显示，rt-PA治疗组62例可评估冠状动脉造影中有61%的梗死相关血管通畅，而对照组这一比例为21%。rt-PA治疗未伴随任何严重并发症。在rt-PA组中，导管插入术结束时循环纤维蛋白原水平为起始值的52±29%（均值±标准差）。
